Edgewell Personal Care vs Stepan
EPC and SCL side by side, both in soap, detergents, and cleaning preparations; perfumes, cosmetics, and other toilet preparations. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EPC and SCL compare
Edgewell Personal Care and Stepan are about the same size, with market caps of $1.3B and $1.5B.
Edgewell Personal Care grew revenue faster over the last twelve months (11.6% versus 10.0% for Stepan).
Stepan keeps more of each dollar of sales as profit, with a net margin of 0.17% compared with −4.2% at Edgewell Personal Care.
Both pay dividends: Edgewell Personal Care yields 2.1% and Stepan 2.4%.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EPC | SCL |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $1.5B |
| Share price | $29.15 | $65.94 |
| Change, 1 year | 54.8% | 50.0% |
| Change, 5 years | −34.0% | −45.5% |
| Beta (5Y) | 0.68 | 0.87 |
| Employees | 6,700 | – |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 2 | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 2 | 2 |
| Valuation | ||
| P/E | – | 347× |
| P/S | 0.6× | 0.6× (better) |
| P/B | 0.9× (better) | 1.2× |
| EV/EBITDA | 21.9× | 13.4× (better) |
| P/FCF | 25.6× (better) | 329× |
| FCF yield | 3.9% (better) | 0.30% |
| Fair value | – | $56.29 |
| Margin of safety | – | −17.1% |
| Growth | ||
| Revenue growth (TTM) | 11.6% (better) | 10.0% |
| Revenue growth, 5Y average | 2.7% | 4.5% (better) |
| Net income growth (TTM) | −244% | −90.4% (better) |
| EPS growth (TTM) | −247% | −90.4% (better) |
| EPS growth, 5Y average | −15.6% (better) | −17.8% |
| Profitability | ||
| Gross margin | 39.5% (better) | 12.0% |
| Operating margin | 0.80% | 0.95% (better) |
| Net margin | −4.2% | 0.17% (better) |
| FCF margin | 2.3% (better) | 0.18% |
| Return on equity | −6.2% | 0.35% (better) |
| Return on invested capital | 0.56% | 1.4% (better) |
| Financial health | ||
| Debt / equity | 0.85 | 0.52 (better) |
| Net debt / EBITDA | 8.47 | 3.53 (better) |
| Interest coverage | 0.3× | – |
| Current ratio | 1.84 (better) | 1.32 |
| Altman Z-score | 1.61 | 2.72 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | 2.4% (better) |
| Payout ratio | – | 830% |
| Years of dividend growth | – | 16 |
| Dividend growth, 5Y average | – | 6.5% |
| Buyback yield | 1.2% | – |
| Shareholder yield | 3.2% (better) | 2.4% |
| Ownership | ||
| Held by institutions | 117% | 87.6% |
| Held by insiders | 1.5% | 4.8% |
| Insider net buying, 12 months | $0 | – |
| Short interest, % of float | 10.9% | 3.1% |
Go deeper
- EPC stock overview
- EPC income statement
- EPC valuation and score
- SCL stock overview
- SCL income statement
- SCL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.